Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
QuintilesIMS
Moodys
Baxter
Fish and Richardson
Chinese Patent Office
McKinsey
Teva
Express Scripts

Generated: June 18, 2018

DrugPatentWatch Database Preview

Olanzapine pamoate - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for olanzapine pamoate and what is the scope of olanzapine pamoate freedom to operate?

Olanzapine pamoate
is the generic ingredient in one branded drug marketed by Eli Lilly Co and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Olanzapine pamoate has seventy-one patent family members in thirty-one countries.

There are thirty-three drug master file entries for olanzapine pamoate. One supplier is listed for this compound.
Synonyms for olanzapine pamoate
10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, 4,4'-methlenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1), monohydrate
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine pamoate monohydrate
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine 4,4'-Methylenebis[3-hydroxy-2-naphthalenecarboxylate] Monohydrate
221373-18-8
4-[(3-CARBOXY-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLIC ACID 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-4-THIA-2,9-DIAZATRICYCLO[8.4.0.0(3),?]TETRADECA-1(14),2,5,7,10,12-HEXAENE HYDRATE
4,4'-Methylenebis[3-hydroxy-2-naphthalenecarboxylic Acid compound with 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine Hydrate
AKOS016340342
D06623
FT-0673224
J-014547
KS-00002WVM
KS-1403
MolPort-035-395-288
Olanzapine pamoate (USAN)
Olanzapine pamoate [USAN]
Olanzapine Pamoate Hydrate
Olanzapine pamoate monohydrate
PL050720
SCHEMBL1635524
UNII-X7S6Q4MHCB
X7S6Q4MHCB

US Patents and Regulatory Information for olanzapine pamoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for olanzapine pamoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for olanzapine pamoate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,617,321 2-methyl-thieno-benzodiazepine formulation ➤ Try a Free Trial
7,303,764 2-methyl-thieno-benzodiazepine formulation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for olanzapine pamoate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0012 Belgium ➤ Try a Free Trial PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
70015 Netherlands ➤ Try a Free Trial PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
C/GB96/058 United Kingdom ➤ Try a Free Trial PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKinsey
Chinese Patent Office
Citi
US Army
Cerilliant
Daiichi Sankyo
Express Scripts
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.